A Real-World Assessment of the demographic, clinical characteristics and outcomes of a Brazilian cohort of Previously Untreated Extensive Stage-Small Cell Lung Cancer receiving Durvalumab combined with Platinum-Etoposide in (ES-SCLC) in Brazil - EDUR-BRA

Study identifier:D4191R00053

ClinicalTrials.gov identifier:NCT06008353

EudraCT identifier:N/A

CTIS identifier:N/A

Recruiting

Official Title

A Real-World Assessment of the demographic, clinical characteristics and outcomes of a Brazilian cohort of Previously Untreated Extensive Stage-Small Cell Lung Cancer receiving Durvalumab combined with Platinum-Etoposide in (ES-SCLC) in Brazil

Medical condition

Extensive-stage Small-cell Lung Cancer

Phase

N/A

Healthy volunteers

No

Study drug

-

Sex

All

Estimated Enrollment

60

Study type

Observational

Age

18 Years - n/a

Date

Study Start Date: 18 Jan 2024
Estimated Primary Completion Date: 31 Aug 2026
Estimated Study Completion Date: 31 Aug 2026

Study design

Allocation: Non-randomized
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Aug 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

AstraZeneca

Inclusion and exclusion criteria